Last updated: February 20, 2026
What is NDC 11534-0165?
NDC 11534-0165 is marketed as Vyvgart (efgartigimod alfa-fcab), developed by argenx. It is an FcRn antagonist approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-AChR or anti-MuSK antibody-positive.
Market Overview
Indication and Patient Population
- Disease: Generalized myasthenia gravis, a rare autoimmune disorder affecting neuromuscular transmission.
- Prevalence: Estimated 10-20 cases per 100,000 individuals globally.
- Target Demographics: Adults, primarily with refractory or antibody-positive cases.
- Market Size: Approximate US prevalence suggests 70,000-140,000 patients.
Competitive Landscape
- Existing Treatments: Acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, plasma exchange, and intravenous immunoglobulin (IVIG).
- Other Drugs: Efgartigimod (Brand: Vyvgart), Ravulizumab (Mousavii), complement inhibitors.
- Market Share: Vyvgart has gained FDA approval in December 2021, positioning as a targeted therapy with potentially fewer systemic side effects.
Market Penetration
- Initial Launch: Launched in late 2021 in the U.S.
- Adoption Factors: Orphan drug designation, positive Phase III data, high unmet need.
- Pricing Strategy: Premium pricing aligned with orphan drugs.
Price Analysis
Current Pricing
- List Price: Approximate $175,000 to $200,000 annually.
- Cost per Dose: Varies based on infusion frequency, typically 1-2 doses per month.
- Reimbursement Environment: Covered by Medicare, private insurers, but high out-of-pocket for some patients.
Pricing Comparisons
| Drug |
Indication |
Annual Cost |
Price Per Dose |
| Vyvgart |
gMG |
~$180,000 |
$37,500 (monthly) |
| Rituximab (off-label) |
gMG |
~$30,000 |
— |
| Complement Inhibitors |
Rare gMG |
~$500,000 |
— |
Price Projections (Next 3-5 Years)
- Scenario 1 — Stable Pricing: Maintains ~$180,000 annually, driven by high demand in rare diseases.
- Scenario 2 — Price Reductions: 10-15% decrease due to biosimilar entry or increased competition, reducing costs to ~$150,000/year.
- Scenario 3 — Price Escalation: Addition of combination therapies or expanded indications may raise prices to ~$200,000.
- Impact Factors: Payer negotiations, biosimilar development, regulatory changes, patent expirations (not currently applicable; Vyvgart's composition is a monoclonal antibody, with patent protections), and new entrants.
Revenue Projections
Based on market penetration estimates:
- Year 1: 10,000 patients treated, revenues of ~$1.8 billion.
- Year 3: 20,000 patients, ~$3.6 billion.
- Year 5: 25,000+ patients, ~$4.5 billion.
Market growth depends heavily on adoption rates, reimbursement policies, and competition.
Regulatory and Policy Factors
- Orphan Drug Status: Provides exclusivity until 2029, delaying biosimilar competition.
- Pricing Regulations: Increasing scrutiny in the U.S. and Europe may influence future prices.
- Reimbursement Trends: Payor policies favor cost-effective treatments, potentially capping prices.
Key Takeaways
- Vyvgart (efgartigimod alfa-fcab) currently priced around $180,000 annually.
- Market size is constrained by the rarity of gMG but benefits from high unmet need and orphan status.
- Price projections suggest stability but face potential downward pressure from biosimilars or policy interventions.
- Revenues could reach approximately $4.5 billion by year 5 under optimistic market penetration assumptions.
- Competitive landscape remains limited but may evolve with alternative treatments or biosimilars.
FAQs
1. When is Vyvgart expected to face biosimilar competition?
Biosimilar development typically takes 8-10 years post-approval. Given current patents held through at least 2029, biosimilars are unlikely before 2030.
2. How does Vyvgart's pricing compare to other orphan drugs?
It is within the typical range for targeted immunotherapies, which often cost between $150,000 and $300,000 annually.
3. Can pricing be adjusted based on patient access programs?
Yes, manufacturer rebate programs and patient assistance can lower actual out-of-pocket costs but may not significantly impact list price.
4. What factors could accelerate market penetration?
Positive Clinical outcomes, favorable reimbursement terms, and expanded indications would boost adoption rates.
5. How might policy changes influence future prices?
Increased regulatory oversight on drug pricing and greater emphasis on cost-effectiveness could pressure prices downward.
References
[1] U.S. Food and Drug Administration. (2021). Vyvgart (efgartigimod alfa-fcab) approval letter.
[2] MarketWatch. (2023). Vyvgart market size and revenue estimates.
[3] IQVIA Institute. (2022). The Growing Role of Orphan Drugs.
[4] EvaluatePharma. (2023). Pricing trends for rare disease treatments.
[5] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for biologics.
